Dec 02, 2010, 11:00 ET from Patheon Inc.

TORONTO, Dec. 2 /PRNewswire-FirstCall/ - Patheon Inc. (TSX: PTI), a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it will report its full year fiscal 2010 financial results on Friday, December 17, 2010.

In conjunction with this announcement, the company will host a conference call for investors on Friday, December 17, 2010 at 10:00 a.m. (EST).  The financial results news release will be issued at approximately 7:00 a.m. (EST) on Friday, December 17, 2010.   

Interested parties are invited to access the live call, via telephone, in listen-only mode, toll free at 1-888-231-8191 (U.S., including Puerto Rico) and 1-647-427-7450 (Canada and International).  Listeners are encouraged to dial in five to fifteen minutes in advance to avoid delays. A live audio will also be available via the web at href=""> (Please note that Windows Media Player or RealPlayer is required).

A telephone replay of the conference call will be available between Friday, December 17, 2010 and Friday, December 24, 2010 by calling 1-800-642-1687 (toll free) or 1-403-451-9481, and by entering identification number 26520340, followed by the number key.  The conference call will also be archived at href="">


Patheon Inc. (TSX: PTI) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry.  The company provides the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies.  Its services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms.  Patheon uses many innovative technologies including single-use disposables, liquid-filled hard capsules and a variety of modified release technologies.

The company's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization.  Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development projects to clinical trials while minimizing the consumption of valuable API.  The company's integrated development and manufacturing network of 11 facilities, and eight development centers across North America and Europe, enable customer products to be launched with confidence anywhere in the world.

SOURCE Patheon Inc.